• Create serum and body fluid proteomic profiling by surface-enhanced laser desorption and ionization with time-of-flight detection (SELDI-TOF) and artificial intelligence at baseline, 1 mo., and then every 3 mo. [ Designated as safety issue: No ]
• Sensitivity and specificity of the serum proteomic signature profiles measured by SELDI-TOF and artificial intelligence at baseline, 1 month, and then every 3 months [ Designated as safety issue: No ]
• Sensitivity & specificity of proteomic signature profiles of serum, body fluid and tumor biopsy compared with CA-125 serum tumor marker profiles by SELDI-TOF & artificial intelligence and serum CA-125 at baseline, 1 mo. and then every 3 mo. [ Designated as safety issue: No ]

• Create serum and body fluid proteomic profiling by surface-enhanced laser desorption and ionization with time-of-flight detection (SELDI-TOF) and artificial intelligence at baseline, 1 mo., and then every 3 mo.
• Sensitivity and specificity of the serum proteomic signature profiles measured by SELDI-TOF and artificial intelligence at baseline, 1 month, and then every 3 months
• Sensitivity & specificity of proteomic signature profiles of serum, body fluid and tumor biopsy compared with CA-125 serum tumor marker profiles by SELDI-TOF & artificial intelligence and serum CA-125 at baseline, 1 mo. and then every 3 mo.

RATIONALE: The presence of specific proteins may allow a doctor to determine whether or not cancer has relapsed.

PURPOSE: This laboratory study is studying how well protein evaluation predicts disease relapse in patients with stage III or stage IV primary peritoneal or fallopian tube cancer or stage II, stage III, or stage IV ovarian epithelial cancer that is in remission.

OBJECTIVES:

• Create serum and body fluid protein profiles of patients with stage III or IV primary peritoneal, fallopian tube, or ovarian epithelial cancer, or stage IIC ovarian clear cell cystadenocarcinoma in first remission through relapse.
• Analyze expressed protein profiles to try to identify a pattern or changes in patterns associated with relapse in this patient population.
• Compare expressed protein profiles in blood and body fluids at relapse with expressed protein patterns in tumor relapse specimen of these patients.
• Determine the associative/predictive value of serum lysophosphatidic acid measurements for ovarian cancer relapse.

OUTLINE: Patients undergo history, physical examination with pelvic examination, laboratory evaluation, and noninvasive imaging at baseline, 1 month, 3 months, and every 3 months thereafter. Samples are analyzed by surface enhanced laser desorption ionization spectrometry to identify protein profiles. Samples are also analyzed for lysophosphatidic acid. Patient evaluation continues until biopsy proven relapse.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cavity Cancer

• Genetic: proteomic profiling
• Other: laboratory biomarker analysis
• Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry
• Procedure: diagnostic imaging

DISEASE CHARACTERISTICS:

• Histologically confirmed stage III or IV primary peritoneal, fallopian tube, or ovarian epithelial cancer, or stage IIC ovarian clear cell cystadenocarcinoma in first clinical remission as defined by:

  • Normal CA-125
  • Normal physical exam
  • Normal post-hysterectomy pelvic examination
  • No evidence of disease on CT scan or other noninvasive reassessment
• No nonepithelial or mixed epithelial/nonepithelial ovarian cancer

• Completion of standard platinum/paclitaxel or carboplatin/paclitaxel-based chemotherapy with complete response

  • No more than 9 weeks since final course of chemotherapy or triple therapy (no more than 12 weeks since final dose of chemotherapy)

PATIENT CHARACTERISTICS:

Age:

• Not specified

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No concurrent biologic therapy

Chemotherapy:

• See Disease Characteristics
• No concurrent chemotherapy

Endocrine therapy:

• No concurrent hormonal therapy, including replacement hormonal therapy

Radiotherapy:

• No concurrent radiotherapy

Surgery:

• See Disease Characteristics
• No concurrent surgery

Other:

• No concurrent alternative therapy
• No other concurrent cancer therapy